Ampio's Ampion shows positive results in arthritis study extension Ampio announced results of the 20 weeks extension of the Ampion SPRING study to be presented at the Western Orthopedic Association Conference in July. This 20-week extension of a multicenter study evaluated the safety and efficacy of a single intra-articular injection of Ampion treatment of inflammation-associated pain in symptomatic OA of the knee. At 20 weeks, the percentage of patients in the moderate-to-severe subgroup who reported a reduction in pain was significantly higher for patients who received Ampion - 50% - compared to those who received vehicle control - 25% -. Similar rates and severity of adverse events were observed in the Ampion and vehicle control groups. A single injection of Ampion was associated with sustained improvements in knee pain over 20 weeks.
Ampio confirms sales agreement with Cantor Fitzgerald Ampio Pharmaceuticals entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald. CEO Michael Macaluso stated "During our most recent conference call, we stated that we are not currently raising money and that we have enough money to get us through 2016 and into 2017 and still complete all of our current objectives and nothing has changed since that conference call. The "at-the-market" program may be used opportunistically and as a contingency facility to strengthen our position post-Ampion trial data."